FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.

In patients with COVID-19, preexisting immunity and Omicron infection were associated with reduced disease severity and upper respiratory symptom presentation.

HHS Secretary Robert F. Kennedy Jr named 8 new members to the CDC’s Advisory Committee on Immunization Practices.

Church & Dwight has initiated a recall of all lots within expiry of Zicam Cold Remedy Nasal Swabs, Zicam Nasal AllClear Swabs, and Orajel Baby Teething Swabs due to potential microbial contamination.

Clinical use of AI-generated draft radiograph reports is associated with improved radiologist documentation efficiency.

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.

The US Food and Drug Administration says it plans to use artificial intelligence to help speed the approval of new drugs and medical devices.

More than 1.7 million window air conditioners are being recalled due to a risk for mold growth, which can lead to serious health problems.

Cessation of public water fluoridation would increase tooth decay and health system costs in the United States.

Treatment with RBL was effective against recurrent CDI among high-risk patients when administered at home or in clinical settings.

Influenza- and ARI-associated hospitalization rates in adults were highest in those with underlying medical conditions, but the risk was mediated by influenza vaccination.

Arakoda ® (tafenoquine) is now available in an 8-count bottle format, according to 60 Degrees Pharmaceuticals. Arakoda, an 8-aminoquinolone antimalarial, was approved in 2018 for the prophylaxis of ...